Cardarine raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-17 and is reviewed periodically as new material appears.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
The project has faced criticism for delays and cost overruns. After multiple delays, the opening date has slipped from an original target of 2023 to a projected completion of construction by end of 2028, with full operations not expected until 2029–2030. Estimated at 200 billion ISK, costs have exceeded all original projections, and critics have questioned the hospital's location as neither central to modern Reykjavík nor likely to ease the city's traffic problems.
== Medical uses == Racecadotril is used for the treatment of acute diarrhea in children and adults and has better tolerability than loperamide, as it causes less constipation and flatulence. Several guidelines have recommended racecadotril use in addition to oral rehydration treatment in children with acute diarrhea.
On April 25, 2023, Carrier Global announced that it intended to acquire the HVAC division Viessmann Climate Solutions from the Viessmann Group and divest its Commercial Refrigeration business and most of its Fire & Security businesses. In December 2023, Carrier Global sold its security businesses LenelS2, Supra and Onity to Honeywell for approximately $5 billion. In March 2025, Carrier Global declared to sell its Industrial Fire division to Sentinel Capital Partners in a $1.43 billion deal.
==== Moisture content differences ==== The chemical potential is explained here since it is the true driving force for the transport of water in both liquid and vapour phases in wood. The Gibbs free energy per mole of substance is usually expressed as the chemical potential of that substance. The chemical potential of water in unsaturated air or wood below the fibre saturation point influences the drying of wood. Equilibrium will occur at the equilibrium moisture content (as defined earlier) of wood when the chemical potential of water in the wood becomes equal to that in the surrounding air. The chemical potential of sorbed water is a function of wood moisture content. Therefore, a gradient of wood moisture content (between surface and centre), or more specifically of water activity, is accompanied by a gradient of chemical potential under isothermal conditions. Moisture will redistribute itself throughout the wood until its chemical potential is uniform throughout, resulting in a zero potential gradient at equilibrium. The flux of moisture attempting to achieve the equilibrium state is assumed to be proportional to the difference in its chemical potential, and inversely proportional to the path length over which the potential difference acts. The gradient in chemical potential is related to the moisture content gradient as explained in above equations. The diffusion model using the moisture content gradient as a driving force was applied successfully by Wu (1989) and Doe et al. (1994).
Sources: en.wikipedia.org
In 2023, world production of peppermint was 35,547 tonnes, led by Morocco with 78% of the total and Argentina with 20% (table). In 2020, Oregon and Washington produced most of American peppermint, the leaves of which are processed for the essential oil to produce flavourings mainly for chewing gum and toothpaste.
== Pathophysiology == Pathophysiology refers to the physiological processes associated with a disease or injury. In the history of medicine, diseases became better understood as human anatomy became better understood. The development of autopsy in the 15th and 16th centuries was key to this learning. As anatomists detailed the complex structures of the human body, they began to pay more attention to the pathological structures associated with diseases, their causes and effects, and mechanisms of progress. By the 18th century, many such pathologic observations were being published in textbooks and journals. This work lay important foundations for advances in medical treatment and intervention. Historically, various notions of present-day "diabetes" have described some general mix of excessive urine (polyuria), excessive thirst (polydipsia), and weight loss (see: History of diabetes#Early accounts). Over the past few centuries, these symptoms have been linked to updated understandings of how the disease works, and how it manifests differently across cases. This section outlines these developments as various diabetic conditions have become better understood.
== Function == Vicilin is a globulin present in legumes that assists the storage of proteins. Vicilins are 7S globulins. Sucrose binding, antifungal capabilities, and oxidative stress are a few of the globulin's functions. Vicilin peptides produced by digestion using trypsin or chymotrypsin offer anti-hypersensitive properties. Vicilin's function was best understood because to the addition of the copper ligand. Vicilin has various significant residues, four of which are involved in copper ion coordination. Vicilin belongs to the cupin family of proteins, in which metal ligand coordination is common, but vicilin is the only seed storage protein in this family known to include copper. This inclusion is crucial for enzymatic activity.
Sources: en.wikipedia.org
DX-9065a was the first synthetic compound that inhibited FXa without inhibiting thrombin. That was attained by inserting a carboxyl group which seemed to be the most important moiety for a selective binding to FXa. Those early developed small molecules yet had amidine-groups or even higher-basic functions, which were thought to be necessary as mimics for an arginine residue in prothrombin, the natural substrate of factor Xa. Nevertheless, these basic functions are also related to a very poor oral bioavailability (e.g. 2–3% for DX-9065a). In 1998 Bayer Healthcare, a pharmaceutical company started searching for low-molecular-weight direct factor Xa inhibitors with higher oral bioavailability. High-throughput screening and further optimisation at first lead to several substances from the class of isoindolinones demonstrating that much less basic substances can also act as potent Xa inhibitors to an IC50 value of up to 2 nM. Although isoindolinones have a better oral bioavailability than the original compounds it was insufficient. However, the project later lead to the class of n-aryloxazolidinones that provides substances with both high potency of inhibiting factor Xa and high bioavailability. One compound of this class, Rivaroxaban (IC50 = 0.7 nM, bioavailability: 60%), was granted marketing authorization for the prevention of venous thromboembolism in Europe and Canada in September 2008.
=== International institutions, associations, and coordinations === Asia/Pacific Group on Money Laundering Moneyval, the Committee of Experts on the Evaluation of Anti–Money Laundering Measures and the Financing of Terrorism, a monitoring body of the Council of Europe Financial Action Task Force on Money Laundering Inter-Governmental Action Group against Money Laundering in West Africa Association of Certified Anti-Money Laundering Specialists
The precise direct molecular mechanism of action by which bromantane ultimately acts as a dopamine synthesis enhancer is unknown. However, it has been determined that activation of certain cAMP-, Ca2+-, and phospholipid-dependent protein kinases such as protein kinase A and especially protein kinase C corresponds with the manifestation of the pharmacological effects of bromantane. Bromantane may activate intracellular signaling cascades by some mechanism (e.g., agonizing some as-yet-undetermined receptor) to in turn activate protein kinases, which in turn cause increased transcription of TH and AAAD. The related drugs amantadine and memantine also have many properties similar to those of bromantane. Researchers discovered that amantadine and memantine bind to and act as agonists of the σ1 receptor (Ki = 7.44 μM and 2.60 μM, respectively) and that activation of the σ1 receptor is involved in the central dopaminergic effects of amantadine at therapeutically relevant concentrations; the authors of the study stated that this could also be the mechanism of action of bromantane, as it is in the same family of structurally related compounds and evidence suggests a role of dopamine in its effects. But this could also be seen as evidence of the contrary since bromantane has effects that are distinctly different from amantadine and memantine.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.